Search

European journal of nuclear medicine and molecular imaging 47(12), 2925-2926 (2020). doi:10.1007/s00259-020-04824-9, Published by Springer-Verl., Heidelberg [u.a.]

Cardiac transthyretin-related (ATTR) amyloidosis is a severe cardiomyopathy for which therapeutic approaches are currently under development. Because non-invasive imaging techniques such as cardiac magnetic resonance imaging and echocardiography are non-specific, the diagnosis of ATTR amyloidosis is still based on myocardial biopsy. Thus, diagnosis of ATTR amyloidosis is difficult in patients refusing myocardial biopsy. Furthermore, myocardial biopsy does not allow 3D-mapping and quantification of myocardial ATTR amyloid. In this report we describe a Tc-99m-DPD-based molecular imaging technique for non-invasive single-step diagnosis, three-dimensional mapping and semiquantification of cardiac ATTR amyloidosis in a patient with suspected amyloid heart disease who initially rejected myocardial biopsy. This report underlines the clinical value of SPECT-based nuclear medicine imaging to enable non-invasive diagnosis of cardiac ATTR amyloidosis, particularly in patients rejecting biopsy.

Cancer medicine 6(7), 1639-1651(2017). doi:10.1002/cam4.1113, Published by Wiley, Hoboken, NJ

Background: Peptide receptor radionuclide therapy (PRRT) plays an important role in the treatment of neuroendocrine tumors (NET). Pre-therapeutic dosimetry using the area under the measured time-activity curve (AUC) is important. The sampling schedule for this dosimetry determines the accuracy and reliability of the obtained AUC. The aim of this study was to investigate the effect of reduced number of measurement points (i.e., gamma camera image acquisition or serum measurements) on treatment planning accuracy in PRRT using In-111-labeled-diethylenetriaminopentaacetic acid-octreotide (DTPAOC; Octreoscan T). Methods: Pre-therapeutic biokinetic data of 15 NET patients were investigated using a recently developed physiologically based pharmacokinetic (PBPK) model. Two parameter sets were determined (standard or iterative approach) and used for calculation of time-integrated activity coefficients (TIACs) for the tumor, kidneys, liver, spleen, serum, and whole body. TIACs obtained using the full data sets were used as reference. To evaluate the effect of sampling on individual treatment planning, reduced sampling schedules were generated omitting either 1, 2, 3, or 4 organ and serum measurements or all serum measurements for each patient. Relative deviations (RDs) between these and reference TIACs were calculated and used as criterion for treatment planning accuracy. An RD

PLoS one 11(1), e0145049 (2016). doi:10.1371/journal.pone.0145049, Published by PLoS, Lawrence, Kan.

European journal of nuclear medicine and molecular imaging 43(2), 240-248 (2016). doi:10.1007/s00259-015-3169-4, Published by Springer-Verl., Heidelberg [u.a.]

OncoTarget : open access impact journal 8(3), 3870-3880 (2017). doi:10.18632/oncotarget.13910, Published by Impact Journals LLC, [S.l.]

European journal of nuclear medicine and molecular imaging 43(12), 2139-2146 (2016). doi:10.1007/s00259-016-3429-y, Published by Springer-Verl., Heidelberg [u.a.]

PLoS one 11(3), e0150746 (2016). doi:10.1371/journal.pone.0150746, Published by PLoS, Lawrence, Kan.

European journal of nuclear medicine and molecular imaging 46(1), 251-265 (2019). doi:10.1007/s00259-018-4176-z, Published by Springer-Verl., Heidelberg [u.a.]

EJNMMI Research 6(1), 30 (2016). doi:10.1186/s13550-016-0185-8, Published by Springer, Berlin ; Heidelberg

Translational Developmental Psychiatry 5, e547 (2015). doi:10.1038/tp.2015.37, Published by Co-Action Publ., Stockholm [u.a.]

European journal of nuclear medicine and molecular imaging 44(Supplement 1), 41-54(2017). doi:10.1007/s00259-017-3695-3 special issue: "Therapy assessment with PET in cancer patients", Published by Springer-Verl., Heidelberg [u.a.]

ChemistryOpen: including thesis treasury 4(4), 394-394 (2015). doi:10.1002/open.201580401, Published by Wiley-VCH-Verl., Weinheim